Efficacy and safety of rivaroxaban and subcutaneous enoxaparin after spinal surgery

Phase 3

Recruiting

• Conditions: Thromboembolism in the puerperium; Intravenous thromboembolism.; O88.23

• Registration Number: IRCT20211109053014N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

All patients undergoing spinal cord surgery
Patient consent to participate in the study
High risk of the patient for venous thromboembolism

Exclusion Criteria

Consumption of anticoagulants in the last 3 months
Urine test with purpura-positive blood or cutaneous hematoma with active bleeding or high risk of bleeding
Existence of active cancer as an underlying disease or cancer treated in the last 6 months
Hospitalization and inactivity for more than 3 days
Smoking more than 20 cigarettes a day
Having a body mass index higher than 35
Pulmonary embolism and lower venous thrombosis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intravenous Thromboembolism. Timepoint: In this study, hemorrhagic events caused by rivaroxaban and enoxaparin before surgery and 4 weeks after. Method of measurement: According to the patient's clinical symptoms.